行情

BVXV

BVXV

BiondVax
NASDAQ

实时行情|Nasdaq Last Sale

7.20
-0.14
-1.91%
休市 16:00 04/03 EDT
开盘
7.59
昨收
7.34
最高
7.59
最低
7.20
成交量
1.72万
成交额
--
52周最高
13.50
52周最低
5.20
市值
7,454.45万
市盈率(TTM)
7.02
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BVXV价格均价为30.00,最高价位30.00,最低价为30.00。

EPS

BVXV 新闻

更多
  • New Directors Elected to BiondVax's Board of Directors
  • PR Newswire · 03/24 21:01
  • BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
  • PR Newswire · 03/19 12:15
  • UPDATE: BiondVax Says Prelim. Data Indicates Both Primary Objectives For Phase 2 Trial Met
  • Benzinga · 02/05 18:02
  • BoindVax Pharma Reports Prelim. Data From Phase 2 Trial Of M-001 Universal Flu Vaccine Candidate
  • Benzinga · 02/05 18:01

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

BVXV 简况

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
展开

微牛提供Biondvax Pharmaceuticals Ltd - ADR(NASDAQ-BVXV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BVXV股票新闻,以帮助您做出投资决策。